Per the U.S. DoD, * Indicates a "small business" classification and ** indicates a "small disadvantaged business". NOTE: the U.S. DoD only publicly reports contracts valued at $6.5 million USD or greater.
The contract language is EXACTLY as it appears on the official U.S. DoD website (http://www.defense.gov/contracts/) unless otherwise noted.
Contractor: Noveome Biotherapeutics, Incorporated
Noveome Biotherapeutics, Inc., Pittsburgh, Pennsylvania, was awarded a $9,655,000 cost-reimbursement (no fee) modification to a previously awarded contract (N62645-13-C-4014) to provide research and development services in support the Naval Medical Research Centerís cellular combat wound initiative within the current Statement of Work. Work will be performed in Pittsburgh, Pennsylvania, and work is expected to be completed April 18, 2018. Fiscal 2016 research, development, test, and evaluation funds in the amount of $9,655,000 will be obligated at the time of award and will not expire at the end of the current fiscal year. This requirement was sole sourced, under the authority of Federal Acquisition Regulation 6.302-1 and 10 U.S.C. 2304 (c)(1), as Noveome Biotherapeutics, Inc. was deemed the only contractor able to perform services within the scope of the original contract. The Naval Medical Logistics Command, Fort Detrick, Maryland, is the contracting activity. (Awarded August 26, 2016)
Total Contract Value: $9,655,000